A multivariate analysis revealed that GCC2-AS1 expression (HR = 1.816 [1.113–2.964], P = 0.017), primary therapy outcome [(HR = 2.442 [1.401–4.254], P = 0.002), and tumor status (HR = 6.028 [3.339–10.884], P<0.001) independently predicted overall time. This evidence concerns the gene GCC2 and neoplasm.